Literature DB >> 27043897

Hyperoxia Is Associated With Poor Outcomes in Pediatric Cardiac Patients Supported on Venoarterial Extracorporeal Membrane Oxygenation.

Nathaniel R Sznycer-Taub1, Ray Lowery, Sunkyung Yu, Sonal T Owens, Jennifer C Hirsch-Romano, Gabe E Owens.   

Abstract

OBJECTIVES: Patients who require venoarterial extracorporeal membrane oxygenation because of cardiac failure frequently have supranormal blood oxygen tensions (hyperoxia). Recent studies have suggested worse outcomes in patients with hyperoxia after resuscitation from cardiac or respiratory arrests, presumably because of oxidative stress. There are limited data regarding the effect of hyperoxia on outcomes in pediatric patients on venoarterial extracorporeal membrane oxygenation.
DESIGN: Retrospective chart review.
SETTING: Pediatric cardiothoracic ICU. PATIENTS: Cardiac surgery patients less than 1 year old requiring venoarterial extracorporeal membrane oxygenation in the postoperative period from 2007 to 2013.
MEASUREMENTS AND MAIN RESULTS: In 93 infants (median time on extracorporeal membrane oxygenation, 5 d), mortality at 30 days post surgery (primary outcome) was 38%. Using a receiver operating characteristic curve, a mean PaO2 of 193 mm Hg in the first 48 hours of extracorporeal membrane oxygenation was determined to have good discriminatory ability with regard to 30-day mortality. Univariate analysis identified a mean PaO2 greater than 193 mm Hg (p = 0.001), longer cardiopulmonary bypass times (p = 0.09), longer duration of extracorporeal membrane oxygenation (p < 0.0001), and higher extracorporeal membrane oxygenation pump flows (p = 0.052) as possible risk factors for 30-day mortality. In multivariable analysis controlling for the variables listed above, a mean PaO2 greater than 193 mm Hg remained an independent risk factor for mortality (p = 0.03). In addition, a mean PaO2 greater than 193 mm Hg was associated with the need for renal dialysis (p = 0.02) but not with neurologic injury (p = 0.41) during the hospitalization.
CONCLUSIONS: In infants with congenital heart disease who are placed on venoarterial extracorporeal membrane oxygenation postoperatively, hyperoxia (defined as a mean PaO2 > 193 mm Hg in the first 48 hr of extracorporeal membrane oxygenation) was an independent risk factor for 30-day mortality after surgery. Future studies are needed to delineate the causative or associative role of hyperoxia with outcomes, especially in children with baseline cyanosis who may be more susceptible to the effects of oxidative stress.

Entities:  

Mesh:

Year:  2016        PMID: 27043897     DOI: 10.1097/PCC.0000000000000655

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  11 in total

1.  Conservative versus liberal oxygenation targets in critically ill children: the randomised multiple-centre pilot Oxy-PICU trial.

Authors:  Mark J Peters; Gareth A L Jones; Daisy Wiley; Jerome Wulff; Padmanabhan Ramnarayan; Samiran Ray; David Inwald; Michael Grocott; Michael Griksaitis; John Pappachan; Lauran O'Neill; Simon Eaton; Paul R Mouncey; David A Harrison; Kathryn M Rowan
Journal:  Intensive Care Med       Date:  2018-06-04       Impact factor: 17.440

2.  Oxygen: A Luxurious Life-Giving and Potentially Toxic Gas.

Authors:  Joan Sanchez-de-Toledo; Hülya Bayir
Journal:  Pediatr Crit Care Med       Date:  2016-04       Impact factor: 3.624

3.  Hyperoxia and Hypocapnia During Pediatric Extracorporeal Membrane Oxygenation: Associations With Complications, Mortality, and Functional Status Among Survivors.

Authors:  Katherine Cashen; Ron Reeder; Heidi J Dalton; Robert A Berg; Thomas P Shanley; Christopher J L Newth; Murray M Pollack; David Wessel; Joseph Carcillo; Rick Harrison; J Michael Dean; Robert Tamburro; Kathleen L Meert
Journal:  Pediatr Crit Care Med       Date:  2018-03       Impact factor: 3.624

4.  Does supply meet demand? A comparison of perfusion strategies on cerebral metabolism in a neonatal swine model.

Authors:  Constantine D Mavroudis; Tiffany Ko; Lindsay E Volk; Benjamin Smood; Ryan W Morgan; Jennifer M Lynch; Mahima Davarajan; Timothy W Boorady; Daniel J Licht; J William Gaynor; Christopher E Mascio; Todd J Kilbaugh
Journal:  J Thorac Cardiovasc Surg       Date:  2020-12-11       Impact factor: 5.209

5.  Association Between Hyperoxemia and Increased Cell-Free Plasma Hemoglobin During Cardiopulmonary Bypass in Infants and Children.

Authors:  Catherine Gretchen; Hϋlya Bayir; Patrick M Kochanek; Kristine Ruppert; Melita Viegas; David Palmer; Nahmah Kim-Campbell
Journal:  Pediatr Crit Care Med       Date:  2022-02-01       Impact factor: 3.624

6.  Use of Extracorporeal Membrane Oxygenation After Congenital Heart Disease Repair: A Systematic Review and Meta-Analysis.

Authors:  Yuhao Wu; Tianxin Zhao; Yonggang Li; Shengde Wu; Chun Wu; Guanghui Wei
Journal:  Front Cardiovasc Med       Date:  2020-11-11

7.  Association of Arterial Hyperoxia With Outcomes in Critically Ill Children: A Systematic Review and Meta-analysis.

Authors:  Thijs A Lilien; Nina S Groeneveld; Faridi van Etten-Jamaludin; Mark J Peters; Corinne M P Buysse; Shawn L Ralston; Job B M van Woensel; Lieuwe D J Bos; Reinout A Bem
Journal:  JAMA Netw Open       Date:  2022-01-04

Review 8.  Inflammation and Oxidative Stress in the Context of Extracorporeal Cardiac and Pulmonary Support.

Authors:  Sanaz Hatami; Joshua Hefler; Darren H Freed
Journal:  Front Immunol       Date:  2022-03-04       Impact factor: 7.561

9.  The Outcome of Post-cardiotomy Extracorporeal Membrane Oxygenation in Neonates and Pediatric Patients: A Systematic Review and Meta-Analysis.

Authors:  Hwa Jin Cho; Insu Choi; Yujin Kwak; Do Wan Kim; Reverien Habimana; In-Seok Jeong
Journal:  Front Pediatr       Date:  2022-04-25       Impact factor: 3.418

10.  PaO2 greater than 300 mmHg promotes an inflammatory response during extracorporeal circulation in a rat extracorporeal membrane oxygenation model.

Authors:  Yutaka Fujii; Eisuke Tatsumi; Fujio Nakamura; Takashi Oite
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.